Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition.
Two top pharma companies have exited the UK's voluntary medicines pricing agreement in protest at what the industry has said is a "punitive" system of revenue clawbacks, casting doubt on th
The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the